{"mainPropery":{"diseaseId":6821,"diseaseName":"Muir-Torre syndrome","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/6821/muir-torre-syndrome","synonyms":["Cutaneous sebaceous neoplasms and keratoacanthomas multiple with gastrointestinal and other carcinomas","Keratoacanthoma"],"synonyms-with-source":[{"name":"Cutaneous sebaceous neoplasms and keratoacanthomas multiple with gastrointestinal and other carcinomas"},{"name":"Keratoacanthoma"}],"identifiers":[{"identifierType":"OMIM","identifierId":"158320"},{"identifierType":"ORPHANET","identifierId":"587"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":6,"diseaseTypeName":"Digestive Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"},{"diseaseTypeId":22,"diseaseTypeName":"Skin Diseases","source":"Orphanet"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":121,"resourceName":"Fight Colorectal Cancer","abbreviation":"","address1":"134 West Park Central Square","address2":" Suite 210","address3":"","address4":"","address5":"","city":"Springfield","state":"MO","zip":"65806","country":"United States","phone":"+1-703-548-1225 (Office)","tty":"","tollFree":"1-877-427-1211 (Helpline)","fax":"","email":"Info@FightCRC.org","url":"https://fightcolorectalcancer.org/","freeText":""},{"resourceID":122,"resourceName":"Colon Cancer Alliance","abbreviation":"","address1":"1025 Vermont Ave, NW","address2":"Suite 1066","address3":"","address4":"","address5":"","city":"Washington","state":"DC","zip":"20005","country":"United States","phone":" +1-202-628-0123 (Office)","tty":"","tollFree":"(877) 422-2030 (Helpline)","fax":"","email":"","url":"https://www.ccalliance.org/","freeText":""},{"resourceID":637,"resourceName":"Lynch Syndrome International","abbreviation":"LSI","address1":"P.O. Box 19","address2":"","address3":"","address4":"","address5":"","city":"Madison","state":"CT","zip":"06443","country":"United States","phone":"","tty":"","tollFree":"","fax":"","email":"info@lynchcancers.com","url":"https://lynchcancers.com/","freeText":"If you would like someone to call you from LSI, please email the Executive Director (susanmcdevitt.lsi@gmail.com) or a leave a message in the Facebook messaging section."},{"resourceID":752,"resourceName":"Collaborative Group of the Americas in Inherited Colorectal Cancer (CGA)","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"","url":"http://www.cgaicc.com"},{"resourceID":3307,"resourceName":"Hereditary Colon Cancer Foundation","abbreviation":"","address1":"3519 NE 15th Avenue","address2":"Unit 518","address3":"","address4":"","address5":"","city":"Portland","state":"OR","zip":"97212","country":"United States","phone":"+1-334-740-8657","tty":"","tollFree":"","fax":"","email":"info@HCCTakesGuts.org","url":"https://www.hcctakesguts.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/158320' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Muir-Torre%20syndrome%20%5Bti%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Muir-Torre syndrome. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":498,"resourceId":1273,"resourceName":"Muir-Torre syndrome - Resources","descriptionText":"The <a href='http://www.cancer.net/patient/Cancer+Types/Muir-Torre+Syndrome ' target='_blank'>American Society of Clinical Oncology</a> provides information on Muir-Torre syndrome. Click on the link to view this information. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":626,"resourceId":637,"resourceName":"Lynch Syndrome International","descriptionText":"<a href='http://www.lynchcancers.com/index.php?option=com_content&amp;view=article&amp;id=19&amp;Itemid=19 ' target='_blank'>Lynch Syndrome International</a> (LSI) Web site lists Lynch syndrome clinical trials and patient registries. Click on the link above to view the list. ","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1093640-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=587' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1211/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/reporter.cfm' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1550,"resourceId":2178,"resourceName":"DermNet New Zealand","descriptionText":"<a href='http://www.dermnetnz.org/systemic/torre-muir.html' target='_blank'>DermNet NZ</a> is an online resource about skin diseases developed by the New Zealand Dermatological Society Incorporated. DermNet NZ provides information about this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1553,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/' target='_blank'>National Cancer Institute</a> (CIS)  provides the most current information on cancer for patients, health professionals, and the general public. You can reach them by calling toll-free at 1-800-422-6237 or by visiting their Web site. ","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:158320' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Muir-Torre syndrome. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Muir-Torre syndrome:<br />\r\n<a href='https://www.aliveandkickn.org/' target='_blank'>HEROIC Registry, Hereditary Cancer Research Champions</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":4601,"questionText":"What is Muir-Torre syndrome?","answerText":"<strong>Muir-Torre syndrome</strong> (MTS) is a form of <a href=\"https://rarediseases.info.nih.gov/gard/9905/hnpcc/Resources/1\" target=\"_blank\">Lynch syndrome</a> and is characterized by sebaceous (oil gland) skin tumors in association with internal cancers.[9046][9049][9050] The most common internal site involved is the gastrointestinal tract (with almost half of affected people having <a href=\"http://www.cancer.gov/types/colorectal\" target=\"_blank\">colorectal cancer</a>), followed by the <a href=\"http://www.merriam-webster.com/medlineplus/genitourinary\" target=\"_blank\">genitourinary tract</a>. Skin lesions may develop before or after the diagnosis of the internal cancer.[9046] MTS is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\">MLH1</a></em> or <em><a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\">MSH2</a></em> genes and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[9049] A mutation in either of these genes gives a person an increased lifetime risk of developing the skin changes and types of cancer associated with the condition.[9050]","dateModified":"2015-06-11T00:00:00"},"basicQuestions":[{"questionId":4602,"questionText":"What are the signs and symptoms of Muir-Torre syndrome?","answerText":"<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002292.htm\" target=\"_blank\">Sebaceous adenoma</a> is the most characteristic finding in people with Muir-Torre syndrome (MTS). Other types of skin tumors in affected people include sebaceous epitheliomas, <a href=\"http://www.skincarephysicians.com/skincancernet/whatis_sebaceous_carcinoma.html\" target=\"_blank\">sebaceous carcinomas</a> (which commonly occur on the eyelids) and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/2307.htm\" target=\"_blank\">keratoacanthomas</a>. Sebaceous carcinoma of the eyelid can invade the orbit of the eye and frequently metastasize, leading to death. Tumors at other sites can also metastasize, but are less likely to cause death. Common sites of keratocathomas include the face and the upper side of the hands, but they can occur anywhere on the body.[9063]<br />\r\n<br />\r\nThe most common internal cancer in people with MTS is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000262.htm\" target=\"_blank\">colorectal cancer</a>, occurring in almost half of affected people. The second most common site is the genitourinary tract. Other cancers that may occur include <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm\" target=\"_blank\">breast cancer</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/lymphoma.html\" target=\"_blank\">lymphoma</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/leukemia.html\" target=\"_blank\">leukemia</a> (rarely), salivary gland tumors, lower and upper respiratory tract tumors, and <a href=\"http://www.childrenshospital.org/az/Site747/mainpageS747P0.html\" target=\"_blank\">chondrosarcoma</a>. Intestinal polyps as well as various benign tumors may also occur.[9063]","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4603,"questionText":"What causes Muir-Torre syndrome?","answerText":"Muir-Torre syndrome is a subtype of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and may be caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\" style=\"font-style: italic;\">MLH1</a>,&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\">MSH2</a>, </em>or&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH6\" target=\"_blank\">MSH6</a></em>&nbsp;gene.[9049][9065] These genes give the body instructions to make proteins needed for repairing <a href=\"https://www.genome.gov/25520880\" target=\"_blank\">DNA</a>. The proteins help fix mistakes that are made when DNA is copied before cells divide. When one of these genes is mutated and causes the related protein to be absent or nonfunctional, the number of DNA mistakes that do not get repaired increases substantially. The affected cells do not function normally, increasing the risk of tumor formation. The <em>MSH2</em> gene is responsible for MTS in the majority of cases.[9063][9064] Mutations in <em>MLH1</em> and <em>MSH2</em> have the most severe effect.[9065]<br />\r\n<br />\r\nNot everyone diagnosed with MTS will have a detectable mutation in one of these genes.[9050] Other, unidentified genes may also play a role in the development of the condition.","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9049,"authors":"Victor A. McKusick","articleTitle":"MUIR-TORRE SYNDROME; MRTES","bookWebsiteJournalTitle":"OMIM","date":"October 10, 2014","volume":"","pages":"","url":"http://www.omim.org/entry/158320","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9064,"authors":"","articleTitle":"MSH2","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/gene/MSH2","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9065,"authors":"Patricia Tai","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"UpToDate","date":"January 5, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":4613,"questionText":"How is Muir-Torre syndrome inherited?","answerText":"Muir-Torre-syndrome (MTS) is a variant of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. This means that having only one changed (mutated) copy of the responsible gene in each cell is enough for a person to develop the condition. When a person with an autosomal dominant condition has children, each child has 50% (1 in 2) chance to inherit the mutated copy of the responsible gene. It is important to note that people who inherit a mutated gene that causes MTS inherit an increased risk of cancer, not the disease itself. Not all people who inherit a mutation in an associated gene will develop cancer. This phenomenon is called <a href=\"http://ghr.nlm.nih.gov/handbook/inheritance/penetranceexpressivity\" target=\"_blank\">reduced penetrance</a>.<br />\r\n<br />\r\nThe majority of people diagnosed with a form of Lynch syndrome have inherited the mutated gene from a parent. However, because not all people with a mutation develop cancer, and the variable age at which cancer may develop, not all people with a mutation have a parent who had cancer.[9066] Thus, the family history may appear negative. A positive family history of MTS is identified in roughly 50% of affected people.[9063] The percentage of people with Lynch syndrome who have a new mutation in the gene that occurred for the first time (and was not inherited from a parent) is unknown but is estimated to be extremely low.[9066]","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9066,"authors":"","articleTitle":"Lynch Syndrome","bookWebsiteJournalTitle":"GeneReviews","date":"May 22, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1211/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4604,"questionText":"How is Muir-Torre syndrome diagnosed?","answerText":"A person is suspected to have Muir-Torre syndrome (MTS) if he/she has one or more of the following:\r\n<ul>\r\n    <li>History of one or more sebaceous tumors</li>\r\n    <li>Age younger than 60 years at first presentation of sebaceous tumors</li>\r\n    <li>Personal history of Lynch-related cancers</li>\r\n    <li>Family history of Lynch-related cancers[9065]</li>\r\n</ul>\r\nThe presence of specific skin tumors in MTS may lead to the correct diagnosis even in the absence of a clear family history. A person diagnosed with MTS can also have genetic testing to see if they have a mutation in one of the genes known to cause MTS. However, not everyone with Muir-Torre syndrome will have a detectable mutation in one of these genes.[9050] Other, unidentified genes may also play a role in the development of the condition.","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9065,"authors":"Patricia Tai","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"UpToDate","date":"January 5, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":4615,"questionText":"What is the long-term outlook for people with Muir-Torre syndrome?","answerText":"About 60% of people with MTS develop metastatic disease. &nbsp;Prognosis may depend on the associated internal cancer(s) each affected person has. People with MTS should have regular screening&nbsp;examinations, particularly of the gastrointestinal and <a href=\"http://www.merriam-webster.com/medlineplus/genitourinary\" target=\"_blank\">genitourinary</a>&nbsp;tracts.[3575]","dateModified":"2011-06-03T13:09:00","resourceClassificationName":"Prognosis","references":[{"referenceId":3575,"authors":"Prieto VG","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"eMedicine","date":"January 29, 2010","url":"http://emedicine.medscape.com/article/1093640-overview","dateAccessed":"2011-06-02T00:00:00"}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":52050,"abbreviatedInquiry":"I have been diagnosed with this syndrome but no one in my family history has exhibited any of the cancers related to this. Could Muir-Torre syndrome be caused by exposure to certain herbicides, specifically Agent Orange?","caseQuestions":[{"questionId":4603,"questionText":"What causes Muir-Torre syndrome?","answerText":"Muir-Torre syndrome is a subtype of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and may be caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\" style=\"font-style: italic;\">MLH1</a>,&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\">MSH2</a>, </em>or&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH6\" target=\"_blank\">MSH6</a></em>&nbsp;gene.[9049][9065] These genes give the body instructions to make proteins needed for repairing <a href=\"https://www.genome.gov/25520880\" target=\"_blank\">DNA</a>. The proteins help fix mistakes that are made when DNA is copied before cells divide. When one of these genes is mutated and causes the related protein to be absent or nonfunctional, the number of DNA mistakes that do not get repaired increases substantially. The affected cells do not function normally, increasing the risk of tumor formation. The <em>MSH2</em> gene is responsible for MTS in the majority of cases.[9063][9064] Mutations in <em>MLH1</em> and <em>MSH2</em> have the most severe effect.[9065]<br />\r\n<br />\r\nNot everyone diagnosed with MTS will have a detectable mutation in one of these genes.[9050] Other, unidentified genes may also play a role in the development of the condition.","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9049,"authors":"Victor A. McKusick","articleTitle":"MUIR-TORRE SYNDROME; MRTES","bookWebsiteJournalTitle":"OMIM","date":"October 10, 2014","volume":"","pages":"","url":"http://www.omim.org/entry/158320","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9064,"authors":"","articleTitle":"MSH2","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/gene/MSH2","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9065,"authors":"Patricia Tai","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"UpToDate","date":"January 5, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":8945,"questionText":"Can exposure to herbicides cause Muir-Torre syndrome?","answerText":"Muir-Torre syndrome (MTS) is a genetic (typically inherited) condition in which mutations in specific genes significantly increase a person's risk to develop the skin changes and cancers associated with the condition. Once a person has a <a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/predisposition\" target=\"_blank\">genetic predisposition</a> to developing cancer, environmental factors can \"trigger\" the&nbsp;development of certain cancers (as is generally the case with all&nbsp;<a href=\"http://www.cancer.org/cancer/cancercauses/geneticsandcancer/heredity-and-cancer\" target=\"_blank\">hereditary cancer predisposition syndromes</a>). To our knowledge, there is no evidence that exposure to herbicides may be directly responsible for causing MTS.","dateModified":"2015-06-15T14:37:00","references":[]},{"questionId":4613,"questionText":"How is Muir-Torre syndrome inherited?","answerText":"Muir-Torre-syndrome (MTS) is a variant of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. This means that having only one changed (mutated) copy of the responsible gene in each cell is enough for a person to develop the condition. When a person with an autosomal dominant condition has children, each child has 50% (1 in 2) chance to inherit the mutated copy of the responsible gene. It is important to note that people who inherit a mutated gene that causes MTS inherit an increased risk of cancer, not the disease itself. Not all people who inherit a mutation in an associated gene will develop cancer. This phenomenon is called <a href=\"http://ghr.nlm.nih.gov/handbook/inheritance/penetranceexpressivity\" target=\"_blank\">reduced penetrance</a>.<br />\r\n<br />\r\nThe majority of people diagnosed with a form of Lynch syndrome have inherited the mutated gene from a parent. However, because not all people with a mutation develop cancer, and the variable age at which cancer may develop, not all people with a mutation have a parent who had cancer.[9066] Thus, the family history may appear negative. A positive family history of MTS is identified in roughly 50% of affected people.[9063] The percentage of people with Lynch syndrome who have a new mutation in the gene that occurred for the first time (and was not inherited from a parent) is unknown but is estimated to be extremely low.[9066]","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9066,"authors":"","articleTitle":"Lynch Syndrome","bookWebsiteJournalTitle":"GeneReviews","date":"May 22, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1211/","authors2":"","placeOfPublication":"","publisher":""}]}]},{"caseId":30944,"abbreviatedInquiry":"I&nbsp;have a patient&nbsp;with Muir-Torre syndrome. Can you provide me with information related to this condition?","caseQuestions":[{"questionId":4601,"questionText":"What is Muir-Torre syndrome?","answerText":"<strong>Muir-Torre syndrome</strong> (MTS) is a form of <a href=\"https://rarediseases.info.nih.gov/gard/9905/hnpcc/Resources/1\" target=\"_blank\">Lynch syndrome</a> and is characterized by sebaceous (oil gland) skin tumors in association with internal cancers.[9046][9049][9050] The most common internal site involved is the gastrointestinal tract (with almost half of affected people having <a href=\"http://www.cancer.gov/types/colorectal\" target=\"_blank\">colorectal cancer</a>), followed by the <a href=\"http://www.merriam-webster.com/medlineplus/genitourinary\" target=\"_blank\">genitourinary tract</a>. Skin lesions may develop before or after the diagnosis of the internal cancer.[9046] MTS is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\">MLH1</a></em> or <em><a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\">MSH2</a></em> genes and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner.[9049] A mutation in either of these genes gives a person an increased lifetime risk of developing the skin changes and types of cancer associated with the condition.[9050]","dateModified":"2015-06-11T00:00:00","references":[{"referenceId":9046,"authors":"","articleTitle":"Torre-Muir syndrome","bookWebsiteJournalTitle":"DermNet NZ","date":"January 24, 2015","volume":"","pages":"","url":"http://www.dermnetnz.org/systemic/torre-muir.html","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9049,"authors":"Victor A. McKusick","articleTitle":"MUIR-TORRE SYNDROME; MRTES","bookWebsiteJournalTitle":"OMIM","date":"October 10, 2014","volume":"","pages":"","url":"http://www.omim.org/entry/158320","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4602,"questionText":"What are the signs and symptoms of Muir-Torre syndrome?","answerText":"<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002292.htm\" target=\"_blank\">Sebaceous adenoma</a> is the most characteristic finding in people with Muir-Torre syndrome (MTS). Other types of skin tumors in affected people include sebaceous epitheliomas, <a href=\"http://www.skincarephysicians.com/skincancernet/whatis_sebaceous_carcinoma.html\" target=\"_blank\">sebaceous carcinomas</a> (which commonly occur on the eyelids) and <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/2307.htm\" target=\"_blank\">keratoacanthomas</a>. Sebaceous carcinoma of the eyelid can invade the orbit of the eye and frequently metastasize, leading to death. Tumors at other sites can also metastasize, but are less likely to cause death. Common sites of keratocathomas include the face and the upper side of the hands, but they can occur anywhere on the body.[9063]<br />\r\n<br />\r\nThe most common internal cancer in people with MTS is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000262.htm\" target=\"_blank\">colorectal cancer</a>, occurring in almost half of affected people. The second most common site is the genitourinary tract. Other cancers that may occur include <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm\" target=\"_blank\">breast cancer</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/lymphoma.html\" target=\"_blank\">lymphoma</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/leukemia.html\" target=\"_blank\">leukemia</a> (rarely), salivary gland tumors, lower and upper respiratory tract tumors, and <a href=\"http://www.childrenshospital.org/az/Site747/mainpageS747P0.html\" target=\"_blank\">chondrosarcoma</a>. Intestinal polyps as well as various benign tumors may also occur.[9063]","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4603,"questionText":"What causes Muir-Torre syndrome?","answerText":"Muir-Torre syndrome is a subtype of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and may be caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <a href=\"http://ghr.nlm.nih.gov/gene/MLH1\" target=\"_blank\" style=\"font-style: italic;\">MLH1</a>,&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH2\" target=\"_blank\">MSH2</a>, </em>or&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/MSH6\" target=\"_blank\">MSH6</a></em>&nbsp;gene.[9049][9065] These genes give the body instructions to make proteins needed for repairing <a href=\"https://www.genome.gov/25520880\" target=\"_blank\">DNA</a>. The proteins help fix mistakes that are made when DNA is copied before cells divide. When one of these genes is mutated and causes the related protein to be absent or nonfunctional, the number of DNA mistakes that do not get repaired increases substantially. The affected cells do not function normally, increasing the risk of tumor formation. The <em>MSH2</em> gene is responsible for MTS in the majority of cases.[9063][9064] Mutations in <em>MLH1</em> and <em>MSH2</em> have the most severe effect.[9065]<br />\r\n<br />\r\nNot everyone diagnosed with MTS will have a detectable mutation in one of these genes.[9050] Other, unidentified genes may also play a role in the development of the condition.","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9049,"authors":"Victor A. McKusick","articleTitle":"MUIR-TORRE SYNDROME; MRTES","bookWebsiteJournalTitle":"OMIM","date":"October 10, 2014","volume":"","pages":"","url":"http://www.omim.org/entry/158320","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9064,"authors":"","articleTitle":"MSH2","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May, 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/gene/MSH2","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9065,"authors":"Patricia Tai","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"UpToDate","date":"January 5, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":4604,"questionText":"How is Muir-Torre syndrome diagnosed?","answerText":"A person is suspected to have Muir-Torre syndrome (MTS) if he/she has one or more of the following:\r\n<ul>\r\n    <li>History of one or more sebaceous tumors</li>\r\n    <li>Age younger than 60 years at first presentation of sebaceous tumors</li>\r\n    <li>Personal history of Lynch-related cancers</li>\r\n    <li>Family history of Lynch-related cancers[9065]</li>\r\n</ul>\r\nThe presence of specific skin tumors in MTS may lead to the correct diagnosis even in the absence of a clear family history. A person diagnosed with MTS can also have genetic testing to see if they have a mutation in one of the genes known to cause MTS. However, not everyone with Muir-Torre syndrome will have a detectable mutation in one of these genes.[9050] Other, unidentified genes may also play a role in the development of the condition.","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9050,"authors":"","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Cancer.Net (American Society of Clinical Oncology)","date":"September, 2014","volume":"","pages":"","url":"http://www.cancer.net/cancer-types/muir-torre-syndrome","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9065,"authors":"Patricia Tai","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"UpToDate","date":"January 5, 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":4613,"questionText":"How is Muir-Torre syndrome inherited?","answerText":"Muir-Torre-syndrome (MTS) is a variant of <a href=\"https://rarediseases.info.nih.gov/gard/9905/lynch-syndrome/resources/1\" target=\"_blank\">Lynch syndrome</a> and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. This means that having only one changed (mutated) copy of the responsible gene in each cell is enough for a person to develop the condition. When a person with an autosomal dominant condition has children, each child has 50% (1 in 2) chance to inherit the mutated copy of the responsible gene. It is important to note that people who inherit a mutated gene that causes MTS inherit an increased risk of cancer, not the disease itself. Not all people who inherit a mutation in an associated gene will develop cancer. This phenomenon is called <a href=\"http://ghr.nlm.nih.gov/handbook/inheritance/penetranceexpressivity\" target=\"_blank\">reduced penetrance</a>.<br />\r\n<br />\r\nThe majority of people diagnosed with a form of Lynch syndrome have inherited the mutated gene from a parent. However, because not all people with a mutation develop cancer, and the variable age at which cancer may develop, not all people with a mutation have a parent who had cancer.[9066] Thus, the family history may appear negative. A positive family history of MTS is identified in roughly 50% of affected people.[9063] The percentage of people with Lynch syndrome who have a new mutation in the gene that occurred for the first time (and was not inherited from a parent) is unknown but is estimated to be extremely low.[9066]","dateModified":"2015-06-15T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9063,"authors":"Victor G Prieto","articleTitle":"Muir-Torre Syndrome","bookWebsiteJournalTitle":"Medscape","date":"May 9, 2014","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1093640-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9066,"authors":"","articleTitle":"Lynch Syndrome","bookWebsiteJournalTitle":"GeneReviews","date":"May 22, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1211/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4614,"questionText":"What types of evaluations are recommended for individuals at-risk for Muir-Torre syndrome?","answerText":"Muir-Torre syndrome should be considered in patients initially seen with sebaceous tumors of the eyelid or other sebaceous adenomas. Immunohistochemistry for MSH2 is a practical initial approach to screen for Muir-Torre syndrome&nbsp;in patients with sebaceous tumors.[3580]<br><br>The following laboratory tests can be of diagnostic value if patients present with cutaneous signs of Muir-Torre syndrome:[3575][3580] \r\n<ul>\r\n<li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003885.htm\" target=_blank>Sigmoidoscopy</a> may be performed for screening of colonic polyposis and colonic carcinoma. \r\n<li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003338.htm\" target=_blank>Endoscopy</a> may be performed to check for an occult gastric carcinoma. \r\n<li>Serum carcinoembryonic antigen values are frequently increased in patients with colonic carcinomas. \r\n<li>A complete blood cell count assists in detecting hematologic malignancies. \r\n<li>A bone marrow examination may be needed to further delineate a hematologic malignancy. \r\n<li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003851.htm\" target=_blank>Laryngoscopy</a> with biopsy examination of any suspicious lesions can rule out an occult laryngeal carcinoma. \r\n<li>Abdominal CT scanning and MRI assist in detecting an occult internal malignancy, such as kidney and urothelial cancers, in patients with Muir-Torre syndrome. \r\n<li>A biopsy of skin tumors performed for histopathologic examination provides an accurate diagnosis of sebaceous neoplasms, including sebaceous adenomas. \r\n<li>Histopathologic examination of specimens obtained from polypectomy (removal of individual polyps) and laryngoscopy of patients with suspected Muir-Torre syndrome confirms the presence or the absence of occult internal malignancy. \r\n<li>Peripheral blood smear, bone marrow examination, and lymph node biopsy may assist in detecting an associated hematologic malignancy in these patients.</li></ul>","dateModified":"2011-06-03T13:07:00","references":[{"referenceId":3575,"authors":"Prieto VG","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"eMedicine","date":"January 29, 2010","url":"http://emedicine.medscape.com/article/1093640-overview","dateAccessed":"2011-06-02T00:00:00"},{"referenceId":3580,"authors":"Font RL, Rishi K","articleTitle":"Sebaceous gland adenoma of the tarsal conjunctiva in a patient with Muir-Torre syndrome","bookWebsiteJournalTitle":"Ophthalmology","date":"2003","url":"http://www.ncbi.nlm.nih.gov/pubmed?term=13129885","dateAccessed":"2011-06-03T00:00:00"}]},{"questionId":4615,"questionText":"What is the long-term outlook for people with Muir-Torre syndrome?","answerText":"About 60% of people with MTS develop metastatic disease. &nbsp;Prognosis may depend on the associated internal cancer(s) each affected person has. People with MTS should have regular screening&nbsp;examinations, particularly of the gastrointestinal and <a href=\"http://www.merriam-webster.com/medlineplus/genitourinary\" target=\"_blank\">genitourinary</a>&nbsp;tracts.[3575]","dateModified":"2011-06-03T13:09:00","resourceClassificationName":"Prognosis","references":[{"referenceId":3575,"authors":"Prieto VG","articleTitle":"Muir-Torre syndrome","bookWebsiteJournalTitle":"eMedicine","date":"January 29, 2010","url":"http://emedicine.medscape.com/article/1093640-overview","dateAccessed":"2011-06-02T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":15147,"phenoTypeName":"Adenoma sebaceum","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8876,"phenoTypeName":"Colon cancer","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":108,"phenoTypeName":"Neoplasm of the stomach","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8875,"phenoTypeName":"Breast carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2721,"phenoTypeName":"Endometrial carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10335,"phenoTypeName":"Hematological neoplasm","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2723,"phenoTypeName":"Laryngeal carcinoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":12110,"phenoTypeName":"Malignant genitourinary tract tumor","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4305,"phenoTypeName":"Neoplasm of the liver","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":15153,"phenoTypeName":"Renal neoplasm","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":167,"phenoTypeName":"Salivary gland neoplasm","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":13296,"phenoTypeName":"Basal cell carcinoma","percentRanges":"-"},{"phenoTypeId":85,"phenoTypeName":"Benign gastrointestinal tract tumors","percentRanges":"-"},{"phenoTypeId":12124,"phenoTypeName":"Benign genitourinary tract neoplasm","percentRanges":"-"},{"phenoTypeId":4111,"phenoTypeName":"Carcinoma","percentRanges":"-"},{"phenoTypeId":11215,"phenoTypeName":"Colonic diverticula","percentRanges":"-"},{"phenoTypeId":12115,"phenoTypeName":"Duodenal adenocarcinoma","percentRanges":"-"},{"phenoTypeId":11974,"phenoTypeName":"Sebaceous gland carcinoma","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Muir-Torre_syndrome"}